Ibuprofen + acetaminophen versus ibuprofen alone for acute low back pain. An ED-based randomized study.
Patients with low back pain (LBP) are often treated with non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs are modestly effective for LBP, but many patients with LBP continue to suffer despite treatment with these medications. We compared pain and functional outcomes one week after ED discharge among patients randomized to a one-week course of ibuprofen + acetaminophen versus ibuprofen + placebo. This was a randomized, double-blind study conducted in two urban EDs. Patients presenting with acute, non-traumatic, non-radicular LBP of no more than 2 weeks duration were eligible for enrollment immediately prior to discharge from an ED if they had a score > 5 on the Roland-Morris Disability Questionnaire (RMDQ), a 24-item validated instrument, indicating more than minimal functional impairment. All patients were given a standardized ten-minute LBP educational session prior to discharge. The primary outcome was improvement on the RMDQ between ED discharge and one week later. One secondary outcome was pain intensity, as measured on a 4-point descriptive scale (severe, moderate, mild, none) at one week. Enrollment began in October 2018. 120 patients met selection criteria and were randomized. Baseline demographic characteristics were comparable between the two groups. By one week after the ED visit, patients randomized to ibuprofen + placebo reported a mean improvement in the RMDQ 9.7 of 11.9 (SD), while those randomized to ibuprofen + acetaminophen reported a mean improvement of 11.1 (SD 10.7). The 95%CI for the between-group difference of 0.8 was -3.0, 4.7. At one week, moderate or severe pain was reported by 15/53 (28%) patients in the ibuprofen + placebo group and 16/57 (28%) patients in the ibuprofen + acetaminophen group (95%CI for between group difference of 0%: -17, 17%). Among ED patients with acute, non-traumatic, non-radicular LBP, adding acetaminophen to ibuprofen does not improve outcomes within one week.